Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson's disease

被引：0
|
作者：
Artaud, F.
Lee, P. C.
Vidailhet, M.
Corvol, J. C.
Elbaz, A.
机构：
来源：
MOVEMENT DISORDERS | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1795
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [1] Dopaminergic agonists in Parkinson's disease
    Alonso Canovas, A.
    Luquin Piudo, R.
    Garcia Ruiz-Espiga, P.
    Burguera, J. A.
    Campos Arillo, V.
    Castro, A.
    Linazasoro, G.
    Lopez del Val, J.
    Vela, L.
    Martinez Castrillo, J. C.
    NEUROLOGIA, 2014, 29 (04): : 230 - 241
  • [2] Dopaminergic agonists in the treatment of Parkinson's disease: A review
    Piccoli, F
    Riuggeri, RM
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 187 - 195
  • [3] Longitudinal association between dopamine agonists and weight in Parkinson's disease
    Artaud, Fanny
    Lee, Pei-Chen
    Mangone, Graziella
    Vidailhet, Marie
    Corvol, Jean-Christophe
    Elbaz, Alexis
    PARKINSONISM & RELATED DISORDERS, 2020, 80 : 158 - 164
  • [4] Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson's disease
    Corvol, J. C.
    Artaud, F.
    Rascol, O.
    Durif, F.
    Derkinderen, P.
    Bourdain, F.
    Brandel, J. -P.
    Pico, F.
    Lacomblez, L.
    Bonnet, C.
    Grabli, D.
    Klebe, S.
    Mangone, G.
    You, H.
    Mesnage, V.
    Lee, P. C.
    Brice, A.
    Vidailhet, M.
    Cormier-Dequaire, F.
    Elbaz, A.
    MOVEMENT DISORDERS, 2017, 32
  • [5] Heterogeneous Longitudinal Cognitive Trajectories in Parkinson's Disease
    Carlisle, Tara C.
    Olson, Kaitlin E.
    Carlson, Nichole E.
    Bettcher, Brianne M.
    Holden, Samantha K.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2022, 34 (03) : 280 - 280
  • [6] The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease
    Bayram, Ece
    Kaplan, Nikki
    Shan, Guogen
    Caldwell, Jessica Z. K.
    AGING NEUROPSYCHOLOGY AND COGNITION, 2020, 27 (04) : 581 - 594
  • [7] Abnormal behavior associated to various dopaminergic agonists in Parkinson's disease
    Panisset, M.
    Savard, G.
    de Courval, F. Poulin
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 307 - 307
  • [8] Arguments favoring early treatment of Parkinson's disease with dopaminergic agonists
    Rascol, O
    REVUE NEUROLOGIQUE, 1999, 155 (01) : 35 - 42
  • [9] In vivo relation between dopaminergic damage and GABA function in early Parkinson's disease
    Yagi, Shunsuke
    Ouchi, Yasuomi
    Yoshikawa, Etsuji
    Takebayashi, Kiyokazu
    Oboshi, Yumi
    Sakamoto, Masanobu
    Magata, Yasuhiro
    NEUROSCIENCE RESEARCH, 2011, 71 : E188 - E188
  • [10] Parkinson's disease severity and use of dopaminergic medications
    Fang, John Y.
    Perez, Adriana
    Christine, Chadwick W.
    Leehey, Maureen
    Aminoff, Michael J.
    Boyd, James T.
    Morgan, John C.
    Dhall, Rohit
    Nicholas, Anthony P.
    Bodis-Wollner, Ivan
    Zweig, Richard M.
    Goudreau, John L.
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (03) : 297 - 299
12345